In yesterday’s Wall Street session, TransMedics Group Inc. (NASDAQ:TMDX) shares traded at $77.27, down -5.99% from the previous session.
As of this writing, 5 analysts cover TransMedics Group Inc. (NASDAQ:TMDX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $85.00 and a low of $74.00, we find $78.00. Given the previous closing price of $82.19, this indicates a potential downside of -5.1 percent. TMDX stock price is now 16.45% away from the 50-day moving average and 55.30% away from the 200-day moving average. The market capitalization of the company currently stands at $2.42B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $78.60 as their price target over the next twelve months.
With the price target maintained at $48, JP Morgan recently Upgraded its rating from Neutral to Overweight for TransMedics Group Inc. (NASDAQ: TMDX). On October 08, 2020, JP Morgan Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $15, while ‘Oppenheimer’ rates the stock as ‘Outperform’.
In other news, Hassanein Waleed H, President & CEO sold 7,500 shares of the company’s stock on Mar 01. The stock was sold for $605,391 at an average price of $80.72. Upon completion of the transaction, the President & CEO now directly owns 381,117 shares in the company, valued at $29.45 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, Chief Financial Officer Gordon Stephen sold 5,000 shares of the business’s stock. A total of $397,550 was realized by selling the stock at an average price of $79.51. This leaves the insider owning 18,789 shares of the company worth $1.45 million. Insiders disposed of 549,870 shares of company stock worth roughly $42.49 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TMDX stock. A new stake in TransMedics Group Inc. shares was purchased by AMERICAN CENTURY COMPANIES INC during the first quarter worth $29,423,000. BRAIDWELL LP invested $23,427,000 in shares of TMDX during the first quarter. In the first quarter, BALYASNY ASSET MANAGEMENT LLC acquired a new stake in TransMedics Group Inc. valued at approximately $7,596,000. OBERWEIS ASSET MANAGEMENT INC/ acquired a new stake in TMDX for approximately $6,367,000. STATE OF NEW JERSEY COMMON PENSION FUND D purchased a new stake in TMDX valued at around $3,008,000 in the second quarter. In total, there are 275 active investors with 94.80% ownership of the company’s stock.
Thursday morning saw TransMedics Group Inc. (NASDAQ: TMDX) opened at $82.69. During the past 12 months, TransMedics Group Inc. has had a low of $16.39 and a high of $82.60. As of last week, the company has a debt-to-equity ratio of 0.31, a current ratio of 10.70, and a quick ratio of 9.80. The fifty day moving average price for TMDX is $66.35 and a two-hundred day moving average price translates $49.76 for the stock.
The latest earnings results from TransMedics Group Inc. (NASDAQ: TMDX) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.25, beating analysts’ expectations of -$0.41 by 0.16. This compares to -$0.46 EPS in the same period last year. The net profit margin was -38.80% and return on equity was -29.80% for TMDX. The company reported revenue of $31.38 million for the quarter, compared to $9.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 224.52 percent. For the current quarter, analysts expect TMDX to generate $24.45M in revenue.
TransMedics Group Inc.(TMDX) Company Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
